ISRCTN72107545已完成未知
A clinical study to assess the bioavailability, tolerability, pharmacokinetics and safety of a solid dose injection of octreotide compared with a reference product
Glide Pharmaceutical Technologies Ltd0 个研究点目标入组 20 人开始时间: 2017年10月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Healthy, male subjects
- •2. Aged 24–45 years
- •3. A body mass index (defined as body mass in kilograms divided by the square of body height in metres) of 18.5–30 kg/m2
- •4. Willing to give written consent after reading the study information and informed consent form (ICF), and discussing the trial with the investigator or an appropriate member of the study staff
- •5. Judged by the investigator to be capable of understanding and complying with the requirements of the trial
- •6. The subject’s primary care physician has confirmed that within the 12 months before first dosing there is nothing in their medical history that would preclude their enrolment into a clinical study
- •7. Able to tolerate a dummy actuation from the Glide SDI device
- •8. Willing to give written consent to have data entered into The Over Volunteering Prevention System
- •9. Subjects must have type I–III grade skin according to the Fitzpatrick prototyping
- •scale to allow for standardisation of photographs taken during the study
排除标准
- •1. Use herbal supplements for 14 days prior to dosing and be unwilling to stop these for the duration of the study
- •2. Have a known hypersensitivity to any of the ingredients or excipients of the study treatment
- •3. Have been exposed to another investigational drug within 90 days prior to start of the treatment period 1
- •4. Have a history of major surgical procedure within 12 weeks prior to the start of the treatment period 1 or have an
- •expectation of a major surgical procedure during the study
- •5. Have a known history of gallstones
- •6. Have a prior or ongoing medical condition (e.g., concomitant illness, psychiatric condition, behavioural disorder, alcoholism, drug abuse), medical history, physical examination findings, ECG findings, or laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results
- •7. History of clinically significant allergies that, in the opinion of the Investigator would contraindicate their participation
- •8. History of, or a reason to believe that a subject has a history of, drug or alcohol abuse within the previous 5 years and at the investigator’s discretion
- •9. Positive test for alcohol or drugs of abuse, including amphetamine, barbiturates, benzodiazepines, cannabis, cocaine, methadone, methamphetamine, opiates (unless this can be explained by the subject’s regular prescribed therapy), phencyclidine and tricyclic antidepressants at Screening or on Day -1 (unless this can be explained by the subject’s medication)
- •10. The use of any over-the-counter medicine in the week prior to drug administration, with the exception of paracetamol (acetaminophen)
- •11. Subjects must be none smokers or an ex-smoker for at least 9 months prior to screening
- •12. The subject’s General Practitioner objects to them entering the trial
- •13. Positive results of HBsAg, hepatitis C antibody, or human immunodeficiency virus (HIV) tests
- •14. Unlikely to co-operate with the requirements of the study
- •15. Tattoos at the site of injection
- •16. Eczema or any significant skin condition that, in the opinion of the investigator, would make it difficult to analyse photographs
研究者
相似试验
已完成
不适用
A study to evaluate the relative bioavailability and effect of food on two 450mg MK-3682 Fixed-Dose Combination Formulations (MK-3682 /MK-5172 /MK-8408)10047438Hepatitis CNL-OMON41967Merck Sharp & Dohme (MSD)24
已完成
不适用
A study to evaluate the relative bioavailability and effect of food on MK-3682B Fixed-Dose Combination Tablet (MK-3682/MK-8408/MK-5172)10047438Hepatitis CNL-OMON41831QPS Netherlands B.V.22
已完成
不适用
A human study to evaluate the bioavailability, anti-inflammation, and safety of Agastache rugosa extracts in healthy women aged more than 20 years and less than 30 years old.KCT0006656Ewha Womens University10
进行中（未招募）
1 期
Phase I Relative Bioavailability and food effect studyEUCTR2016-002895-29-DEBayer AG
进行中（未招募）
1 期
Phase I relative bioavailability and food effect studyEUCTR2016-002813-24-DEBayer AG